ArticleLung2025
Inhibition of Mettl3 by STM2457 and Loss of Macrophage Mettl3 Alleviate Pulmonary Hypertension and Right Heart Remodeling.
Article in Lung, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Targeting the METTL5-MGST1 axis for cancer therapy: molecular mechanisms and therapeutic implications.Molecular biology reports · 2026Review
- The role of mNaunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Epigenetic orchestration of scar formation: Therapeutic potential of targeting DNA methylation and non‑coding RNAs in cutaneous fibrosis (Review).Molecular medicine reports · 2026Review
- SETD2 drives METTL14-mediated mCellular and molecular life sciences : CMLS · 2025Article
- METTL3-mediated m⁶A methylation in cardiac diseases: pathogenic roles and therapeutic potential.Cell biology and toxicology · 2025Review
- Macrophage-driven immunopathology in pulmonary arterial hypertension: from mechanisms to targeted therapies.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundm6A RNA methylation is a critical epigenetic modification involved in the pathogenesis of pulmonary arterial hypertension (PAH). While macrophage-mediated inflammation plays a central role in PAH, the specific contributions of m6A regulators within macrophages are not yet fully understood. This study explores the role of METTL3 in macrophages, with particular emphasis on its contribution to the progression of PAH.
methodsSU5416/Hypoxia (SuHx) PAH mouse models were treated daily with STM2457, a selective METTL3 antagonist, or vehicle for 10 days. Additionally, SuHx PAH was induced in Mettl3flox/floxlyz2cre + and Mettl3flox/flox mice using genetic approaches. Pulmonary acceleration time to pulmonary ejection time (PAAT/PAET) and right ventricular free wall (RVFWD) were measured by ultrasound. Hemodynamic parameters, including right ventricular systolic pressure (RVSP), were assessed. Pulmonary vascular and right heart remodeling were evaluated using HE staining, while vascular and right heart fibrosis were assessed by Masson's trichrome staining. The expression of fibrosis-associated genes was quantified by qPCR. Macrophage activation in tissues was determined via CD86 and CD206 immunofluorescence staining, and the expression of inflammatory cytokines and fibrosis-associated genes was quantified by qPCR.
resultsMETTL3 expression was significantly upregulated in the lungs and macrophages of PAH models. Treatment with STM2457 reversed the progression of SuHx PAH, as evidenced by a reduction in RVSP, attenuation of pulmonary vascular and right heart remodeling, and decreased fibrosis in both the heart and lungs. Furthermore, the expression of fibrosis-associated genes in the right heart, including Col1a1, Col1a3, and α-SMA, was downregulated following STM2457 treatment and METTL3 depletion in macrophages. Both STM2457 treatment and METTL3 depletion resulted in a significant reduction in the number of CD86
conclusionSTM2457 treatment and METTL3 depletion in macrophages effectively reversed SuHx PAH by modulating macrophage inflammatory responses and alleviating pulmonary vascular and right heart remodeling, as well as fibrosis. These findings underscore the role of METTL3 in PAH pathogenesis by regulating macrophage function and inflammation.
Indexed as
Identifiers
39966176What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.